We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca’s planned acquisition of Alexion Pharmaceuticals, a prominent developer of drugs for rare diseases, has received a green light from the European Commission. Read More
Emergent BioSolutions was hit with a potential class-action lawsuit on Wednesday, alleging the company made false and misleading statements regarding its manufacturing capabilities and quality control processes at its Bayview facility in Baltimore, Md. Read More
GlaxoSmithKline (GSK) and Alector have forged a $2.2 billion pact to develop monoclonal antibodies for treating Parkinson’s and Alzheimer’s diseases, among other neurological conditions. Read More
Biogen said it plans to price the monthly infusion at $4,312 or $56,000 annually, a price that many critics say will quickly bankrupt Medicare. Read More
GlaxoSmithKline (GSK) yesterday unveiled plans for what it calls the “New GSK,” including focused investment in the development of vaccines and specialty medicines, which it predicts will make up the largest share of the company’s revenue within five years. Read More
Lehi, Utah-based Civica Rx is a collaborator in a U.S. government-funded partnership with Phlow, which secured a $354 million government contract in May 2020. Read More